The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
me change notification emails
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
Description of Modification
Modification to Previous
Funding Opportunity Number:
Feb 16, 2010
Feb 17, 2010
Original Closing Date for Applications:
Jul 28, 2010
Current Closing Date for Applications:
Jul 28, 2010
Aug 27, 2010
Funding Instrument Type:
Category of Funding Activity:
Science and Technology and other Research and Development
Expected Number of Awards:
Estimated Total Program Funding:
Military Medical Research and Development
Cost Sharing or Matching Requirement:
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Dept. of the Army -- USAMRAA
The ARP Idea Development Award mechanism was first offered in FY07. Since then, 109 Idea Development Award applications have been received, and 13 have been recommended for funding.
The ARP Idea Development Award supports the development of innovative, high-impact ideas that advance the understanding of ASD and that ultimately will lead to improved outcomes for individuals with autism.
Research involving human subject participation is permitted under this funding opportunity, but is restricted to studies without Clinical Trials. In general, a clinical trial is defined as a prospective study where an intervention (e.g., device, drug, behavioral, surgical procedure, or other) is tested on human subjects for a measurable outcome. Principal Investigators (PIs) wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. Refer to the General Application Instructions, Appendix 5, for additional information about studies involving human subjects, human subjects data, or human anatomical substances.
Preliminary data relevant to the proposed research project is required. Preliminary data, unpublished results from the laboratory of the PI, research team, or collaborators named on this application, may be from outside of the ASD research field. Proposals should also be based on a sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.
Multiple PI Option: The FY10 ARP supports collaborative research in order to bring a new perspective to ASD research and/or facilitate progress in the field by combined effort. Therefore, up to three investigators may work on a single project, each of whom will be recognized as a PI and receive a separate award. One member of the team will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with the proposal. The other member(s) will be referred to as the Partnering PI(s). All the investigators must collaborate to submit a single proposal addressing a central problem or question in ASD research. It should be clear that all investigators have an equal level of intellectual input and effort. Multidisciplinary and multi-organizational projects are allowed. If the project is multi-organizational, PIs should include plans for communication between investigators at each organization. Additionally, participating organizations must be willing to resolve potential intellectual and material property issues, and to remove any barriers that might interfere with achieving high levels of cooperation to ensure successful completion of this award.
Important aspects of the Idea Development Award are as follows:
1. Impact: The proposed research is expected to make an important and original contribution to advancing the understanding of ASD and lead ultimately to improved outcomes for individuals with ASD.
2. Innovation: Research deemed innovative may represent a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Research may be innovative in study concept, research methods or technology, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not typically considered innovative.
It is the responsibility of the PI to clearly and explicitly articulate the projectís innovation and the potential impact on ASD.
Link to Additional Information
If you have difficulty accessing the full announcement
electronically, please contact:
PA HELP: 301-619-7079; firstname.lastname@example.org
eReceipt HELP: 301-682-5507; email@example.com
CDMRP Help Desk
Synopsis Modification History
The following files represent the modifications to this synopsis
with the changes noted within the documents. The list of files is
arranged from newest to oldest with the newest file representing the
current synopsis. Changed sections from the previous document are shown
in a light grey background.